Communications with FDA by Early-Stage Companies - Problems and Solutions
Early life science companies face many challenges when trying to obtain marketing authorization, not the least of which is communicating with FDA. This 90-minute webinar will be hosted by Alan Minsk, a partner at the law firm Arnall Golden Gregory, who has more than 16 years of experience advising small to mid-size pharmaceutical and medical device companies on FDA-related legal and regulatory matters. He will discuss common mistakes early-stage companies make when interacting with FDA and recommendations to improve such relationships.
Question and answer session will follow.
Related Services
- Alan G. Minsk
Partner